03835nas a2200301 4500008004100000022001400041245015300055210006900208260001200277520274700289653005303036653004003089653003503129653003403164653003303198653003503231100002003266700002203286700002603308700002103334700001903355700002103374700001903395700002603414700002103440700002403461856004803485 2015 eng d a1872-895200aP300-based brain-computer interface (BCI) event-related potentials (ERPs): People with amyotrophic lateral sclerosis (ALS) vs. age-matched controls.0 aP300based braincomputer interface BCI eventrelated potentials ER c02/20153 a
OBJECTIVE: Brain-computer interfaces (BCIs) aimed at restoring communication to people with severe neuromuscular disabilities often use event-related potentials (ERPs) in scalp-recorded EEG activity. Up to the present, most research and development in this area has been done in the laboratory with young healthy control subjects. In order to facilitate the development of BCI most useful to people with disabilities, the present study set out to: (1) determine whether people with amyotrophic lateral sclerosis (ALS) and healthy, age-matched volunteers (HVs) differ in the speed and accuracy of their ERP-based BCI use; (2) compare the ERP characteristics of these two groups; and (3) identify ERP-related factors that might enable improvement in BCI performance for people with disabilities.
METHODS: Sixteen EEG channels were recorded while people with ALS or healthy age-matched volunteers (HVs) used a P300-based BCI. The subjects with ALS had little or no remaining useful motor control (mean ALS Functional Rating Scale-Revised 9.4 (±9.5SD) (range 0-25)). Each subject attended to a target item as the items in a 6×6 visual matrix flashed. The BCI used a stepwise linear discriminant function (SWLDA) to determine the item the user wished to select (i.e., the target item). Offline analyses assessed the latencies, amplitudes, and locations of ERPs to the target and non-target items for people with ALS and age-matched control subjects.
RESULTS: BCI accuracy and communication rate did not differ significantly between ALS users and HVs. Although ERP morphology was similar for the two groups, their target ERPs differed significantly in the location and amplitude of the late positivity (P300), the amplitude of the early negativity (N200), and the latency of the late negativity (LN).
CONCLUSIONS: The differences in target ERP components between people with ALS and age-matched HVs are consistent with the growing recognition that ALS may affect cortical function. The development of BCIs for use by this population may begin with studies in HVs but also needs to include studies in people with ALS. Their differences in ERP components may affect the selection of electrode montages, and might also affect the selection of presentation parameters (e.g., matrix design, stimulation rate).
SIGNIFICANCE: P300-based BCI performance in people severely disabled by ALS is similar to that of age-matched control subjects. At the same time, their ERP components differ to some degree from those of controls. Attention to these differences could contribute to the development of BCIs useful to those with ALS and possibly to others with severe neuromuscular disabilities.
10aalternative and augmentative communication (AAC)10aamyotrophic lateral sclerosis (ALS)10aBrain-computer interface (BCI)10abrain-machine interface (BMI)10aelectroencephalography (EEG)10aevent-related potentials (ERP)1 aMcCane, Lynn, M1 aHeckman, Susan, M1 aMcFarland, Dennis, J.1 aTownsend, George1 aMak, Joseph, N1 aSellers, Eric, W1 aZeitlin, Debra1 aTenteromano, Laura, M1 aWolpaw, Jonathan1 aVaughan, Theresa, M uhttp://www.ncbi.nlm.nih.gov/pubmed/2570394002595nas a2200421 4500008004100000022001400041245009200055210006900147260001200216300001100228490000700239520137400246653001001620653000901630653003401639653002801673653003001701653002801731653002701759653003501786653001101821653001101832653000901843653001601852653001901868653002301887653002801910653001801938100002001956700002101976700002601997700001902023700001902042700001902061700002102080700002402101856004802125 2014 eng d a2167-922300aBrain-computer interface (BCI) evaluation in people with amyotrophic lateral sclerosis.0 aBraincomputer interface BCI evaluation in people with amyotrophi c06/2014 a207-150 v153 aBrain-computer interfaces (BCIs) might restore communication to people severely disabled by amyotrophic lateral sclerosis (ALS) or other disorders. We sought to: 1) define a protocol for determining whether a person with ALS can use a visual P300-based BCI; 2) determine what proportion of this population can use the BCI; and 3) identify factors affecting BCI performance. Twenty-five individuals with ALS completed an evaluation protocol using a standard 6 × 6 matrix and parameters selected by stepwise linear discrimination. With an 8-channel EEG montage, the subjects fell into two groups in BCI accuracy (chance accuracy 3%). Seventeen averaged 92 (± 3)% (range 71-100%), which is adequate for communication (G70 group). Eight averaged 12 (± 6)% (range 0-36%), inadequate for communication (L40 subject group). Performance did not correlate with disability: 11/17 (65%) of G70 subjects were severely disabled (i.e. ALSFRS-R < 5). All L40 subjects had visual impairments (e.g. nystagmus, diplopia, ptosis). P300 was larger and more anterior in G70 subjects. A 16-channel montage did not significantly improve accuracy. In conclusion, most people severely disabled by ALS could use a visual P300-based BCI for communication. In those who could not, visual impairment was the principal obstacle. For these individuals, auditory P300-based BCIs might be effective.10aAdult10aAged10aAmyotrophic Lateral Sclerosis10aBiofeedback, Psychology10abrain-computer interfaces10aCommunication Disorders10aElectroencephalography10aEvent-Related Potentials, P30010aFemale10aHumans10aMale10aMiddle Aged10aOnline Systems10aPhotic Stimulation10aPsychomotor Performance10aReaction Time1 aMcCane, Lynn, M1 aSellers, Eric, W1 aMcFarland, Dennis, J.1 aMak, Joseph, N1 aCarmack, Steve1 aZeitlin, Debra1 aWolpaw, Jonathan1 aVaughan, Theresa, M uhttp://www.ncbi.nlm.nih.gov/pubmed/24555843